Interpreting Results From RAMP 201: Avutometinib +/- Defactinib in Recurrent LGSOC
Expert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape.
Expert Perspectives Emerging Therapies Low Grade Serous Ovarian Cancer Ovarian Cancer Ramp 201 Novel Therapy
Source: onclive.com